Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Intravenous (IV) Therapy: Because IV therapy is more potent, the risks are higher
A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine
ANDREW GALLIMORE: Yeah, exactly
Though still investigational, it is of interest for its potential role in supporting cognitive health and age-related memory challenges
US$ 25.74
US$ 25.16
US$ 20.50
US$ 24.40
